Eicosanoids in prevention and management of diseases

Current Molecular Medicine

Volumn 11, Issue 1, 2011, Pages 13-25

  Szefel, J ^a   Piotrowska, M ^a   Kruszewski, W J ^a,b   Jankun, J ^b,c,d   Lysiak Szydlowska W ^b   Skrzypczak Jankun, E ^c  

^a PCK's Maritime Hospital in Gdynia   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Eicosanoids; Fatty acid metabolism; Human diseases; Oxygenases; Signal transduction

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450; ICOSANOID; LIPOXYGENASE; NEUROPROTECTIN PD1; OXYGENASE; PHOSPHOLIPASE; PROSTAGLANDIN SYNTHASE; RESOLVIN RVE1; UNCLASSIFIED DRUG;

CARCINOGENESIS; CATALYSIS; CLINICAL PRACTICE; DISEASE EXACERBATION; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; ICOSANOID METABOLISM; INFLAMMATION; LIPOGENESIS; PROPHYLAXIS; REVIEW; RISK FACTOR;

AMINO ACID SUBSTITUTION; ANTI-INFLAMMATORY AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; FATTY ACIDS, UNSATURATED; HUMANS; LIPOXYGENASES; POLYMORPHISM, GENETIC; PRIMARY PREVENTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UP-REGULATION;

EID: 79551675364     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652411794474374     Document Type: Review

References (106)

1. Meng X, Riordan NH, Riordan HD, et al. Cell membrane fattyacid composition differs between normal and malignant celllines. P R Health Sci J 2004; 23: 103-6.
2. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implicationsfor chronic diseases. Biomed Pharmacother 2006; 60: 502-7.
3. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006; 83: 1467S-76S.
4. Eyster KM. The membrane and lipids as integral participantsin signal transduction: lipid signal transduction for the nonlipidbiochemist. Adv Physiol Educ 2007; 31: 5-16.
5. Giros A, Grzybowski M, Sohn VR, et al. Regulation ofcolorectal cancer cell apoptosis by the n-3 polyunsaturatedfatty acids Docosahexaenoic and Eicosapentaenoic. Cancer Prev Res (Phila Pa) 2009; 2: 732-42.
6. Pégorier JP, Le May C, Girard J. Control of gene expressionby fatty acids. J Nutr 2004; 134: 2444S-9S.
7. Tang DG, La E, Kern J, Kehrer JP. Fatty acid oxidation andsignaling in apoptosis. Biol Chem 2002; 383: 425-42.
8. Steele VE, Holmes CA, Hawk ET, et al. Lipoxygenaseinhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8: 467-83.
9. Shureiqi I, Lippman SM. Lipoxygenase modulation to reversecarcinogenesis. Cancer Res 2001; 61: 6307-12.
10. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9: 162-76.
11. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-93.
12. Skrzypczak-Jankun E, Chorostowska-Wynimko J, Selman SH, Jankun J. Lipoxygenases - a challenging problem inenzyme inhibition. Curr Enzyme Inhib 2007; 3: 119-32.
13. Jin Y, Arita M, Zhang Q, et al. Anti-angiogenesis effect of thenovel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci 2009; 50: 4743-52.
14. Serhan CN, Yang R, Martinod K, et al. Maresins: novelmacrophage mediators with potent antiinflammatory andproresolving actions. J Exp Med 2009; 206: 15-23.
15. Lucas KK, Dennis EA. Distinguishing phospholipase A2types in biological samples by employing group-specificassays in the presence of inhibitors. Prostaglandins Other Lipid Mediat 2005; 77: 235-48.
16. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of theaberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004; 64: 4270-6.
17. Rodriguez A, Sarda P, Nessmann C, Boulot P, Leger CL, Descomps B. Delta6- and delta5-desaturase activities in thehuman fetal liver: kinetic aspects. J Lipid Res 1998; 39: 1825-32.
18. Aktas H, Halperin JA. Translational regulation of geneexpression by omega-3 fatty acids. J Nutr 2004; 134: 2487S-91S.
19. Buczynski MW, Dumlao DS and Dennis EA. Thematic Review Series: Proteomics. An integrated omics analysis ofeicosanoid biology. J Lipid Res 2009; 50: 1015-38.
20. Schneider C, Pratt DA, Porter NA, Brash AR. Control ofoxygenation in lipoxygenase and cyclooxygenase catalysis. Chem Biol 2007; 14: 473-488.
21. Ereso AQ, Cureton EL, Cripps MW, et al. Lipoxin a(4)attenuates microvascular fluid leak during inflammation. JSurg Res 2009; 156: 183-8.
22. Tian H, Lu Y, Sherwood AM, Hongqian D, Hong S. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes:biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci 2009; 50: 3613-20.
23. Xu ZZ, Zhang L, Liu T, et al. Resolvins RvE1 and RvD1attenuate inflammatory pain via central and peripheralactions. Nat Med 2010; 16: 592-597.
24. Yin H, Gao L, Tai HH, Murphey LJ, Porter NA, Morrow JD. Urinary prostaglandin F2alpha is generated from theisoprostane pathway and not the cyclooxygenase in humans. J Biol Chem 2007; 282: 329-36.
25. Montuschi P, Barnes P, Roberts LJ, 2nd. Insights intooxidative stress: the isoprostanes. Curr Med Chem 2007; 14: 703-717.
26. Warner TD, Mitchell JA. Cyclooxygenases: new forms, newinhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
27. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors:targets for treatment and prevention of colorectal cancer?Mol Cancer Ther 2004; 3: 1031-9.
28. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EPreceptors to inhibit metastasis. Cancer Res 2006; 66: 9794-7.
29. Khunnarong J, Tangjitgamol S, Manusirivithaya S, Suekwattana P, Leelahakorn S. Expression ofcyclooxygenase-1 in epithelial ovarian cancer: aclinicopathological study. Asian Pac J Cancer Prev 2008; 9: 757-62.
30. Yu L, Wu WK, Li ZJ, et al. E series of prostaglandin receptor2-mediated activation of extracellular signal-regulatedkinase/activator protein-1 signaling is required for themitogenic action of prostaglandin E2 in esophagealsquamous-cell carcinoma. J Pharmacol Exp Ther 2008; 327: 258-267.
31. Derecka K, Sheldrick EL, Wathes DC, Abayasekara DR Flint AP. A PPAR-independent pathway to PUFA-induced COX-2expression. Mol Cell Endocrinol 2008; 287: 65-71.
32. Dumaz N, Marais R. Integrating signals between cAMP andthe RAS/RAF/MEK/ERK signalling pathways. Based on theanniversary prize of the Gesellschaft fur Biochemie undMolekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 2005; 272: 3491-504.
33. Ono M. Molecular links between tumor angiogenesis andinflammation: inflammatory stimuli of macrophages andcancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-6.
34. Kimura YN, Watari K, Fotovati A, et al. Inflammatory stimulifrom macrophages and cancer cells synergistically promotetumor growth and angiogenesis. Cancer Sci 2007; 98: 2009-18.
35. Monjazeb AM, High KP, Connoy A, Hart LS, Koumenis Cand Chilton FH. Arachidonic acid-induced gene expression incolon cancer cells. Carcinogenesis 2006; 27: 1950-1960.
36. Leone V, di Palma A, Ricchi P, et al. PGE2 inhibits apoptosisin human adenocarcinoma Caco-2 cell line through Ras-PI3Kassociation and cAMP-dependent kinase A activation. Am JPhysiol Gastrointest Liver Physiol 2007; 293: G673-681.
37. Forones NM, Kawamura KY, Segreto HR, Artigiani Neto R, Focchi GR, Oshima CT. Expression of COX-2 in stomachcarcinogenesis. J Gastrointest Cancer 2008; 39: 4-10.
38. Nardone G, Rocco A, Vaira D, et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecularpathway of H pylori-related gastric carcinogenesis. J Pathol 2004; 202: 305-12.
39. Wang D, Buchanan FG, Wang H, Dey SK, Du Bois RN. Prostaglandin E2 enhances intestinal adenoma growth viaactivation of the Ras-mitogen-activated protein kinasecascade. Cancer Res 2005; 65: 1822-9.
40. Ferrandina G, Ranelletti FO, Lauriola L, et al. Cyclooxygenase-2 (COX-2), epidermal growth factorreceptor (EGFR), and Her-2/neu expression in ovariancancer. Gynecol Oncol 2002; 85: 305-10.
41. Conlin AK, Seidman AD, Bach A, et al. Phase II trial ofweekly nanoparticle albumin-bound paclitaxel withcarboplatin and trastuzumab as first-line therapy for womenwith HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010; 10: 281-7.
42. Järvinen TA, Liu ET. Effects of HER-2/neu onchemosensitivity of tumor cells. Drug Resist Updat 2000; 3: 319-24.
43. Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibitsangiogenesis by inducing endothelial cell apoptosis in humanpancreatic tumor xenografts. Cancer Biol Ther 2004; 3: 1217-24.
44. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascularevents associated with rofecoxib in a colorectal adenomachemoprevention trial. N Engl J Med 2005; 352: 1092-02.
45. Curfman GD, Morrissey S, Drazen JM. Expression ofconcern reaffirmed. N Engl J Med 2006; 354: 1193.
46. Half E, Bercovich D, Rozen P. Familial adenomatouspolyposis. Orphanet J Rare Dis 2009; 4: 22.
47. West NJ, Clark SK, Phillips RK, et al. Eicosapentaenoic acidreduces rectal polyp number and size in familialadenomatous polyposis. Gut 59: 918-25.
48. Meruvu S, Walther M, Ivanov I, et al. Sequence determinantsfor the reaction specificity of murine (12R)-lipoxygenase:targeted substrate modification and site-directedmutagenesis. J Biol Chem 2005; 280: 36633-41.
49. Faronato M, Muzzonigro G, Milanese G, et al. Increasedexpression of 5-lipoxygenase is common in clear cell renalcell carcinoma. Histol Histopathol 2007; 22: 1109-18.
50. Yoshimura R, Inoue K, Kawahito Y, et al. Expression of 12-lipoxygenase in human renal cell carcinoma and growthprevention by its inhibitor. Int J Mol Med 2004; 13: 41-6.
51. McCabe NP, Selman SH, Jankun J. Vascular endothelialgrowth factor production in human prostate cancer cells isstimulated by overexpression of platelet 12-lipoxygenase. Prostate 2006; 66: 779-87.
52. Nie D, Nemeth J, Qiao Y, et al. Increased metastaticpotential in human prostate carcinoma cells byoverexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 2003; 20: 657-63.
53. Philips BJ, Dhir R, Hutzley J, Sen M, Kelavkar UP. Polyunsaturated fatty acid metabolizing 15-Lipoxygenase-1 (15-LO-1) expression in normal and tumorigenic humanbladder tissues. Appl Immunohistochem Mol Morphol 2008; 16: 159-64.
54. Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4)function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 2008; 75: 2263-75.
55. Fujimura T, Takahashi S, Urano T, et al. Expression ofcytochrome P450 3A4 and its clinical significance in humanprostate cancer. Urology 2009; 74: 391-7.
56. Luby TM. Targeting cytochrome P450 CYP1B1 with atherapeutic cancer vaccine. Expert Rev Vaccines 2008; 7: 995-1003.
57. Spector AA, Norris AW. Action of epoxyeicosatrienoic acidson cellular function. Am J Physiol Cell Physiol 2007; 292:C996-1012.
58. Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL. Cytochrome P450 eicosanoids are activators of peroxisomeproliferator-activated receptor alpha. Drug Metab Dispos 2007; 35: 1126-34.
59. Edwards SH, Thompson D, Baker SF, Wood SP, Wilton DC. The crystal structure of the H48Q active site mutant ofhuman group IIA secreted phospholipase A2 at 1.5 Aresolution provides an insight into the catalytic mechanism. Biochemistry 2002; 41: 15468-76.
60. Samanta U, Kirby SD, Srinivasan P, Cerasoli DM, Bahnson BJ. Crystal structures of human group-VIIA phospholipaseA2 inhibited by organophosphorus nerve agents exhibit nonagedcomplexes. Biochem Pharmacol 2009; 78: 420-9.
61. Endsley MP, Aggarwal N, Isbell MA, et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells:Location, hydrolysis and 12-lipoxygenase metabolism. Int JCancer 2007; 121: 984-91.
62. Jankun J, Doerks T, Aleem AM, Lysiak-Szydlowska W and Skrzypczak-Jankun E. Do human lipoxygenases have a PDZregulatory domain? Curr Mol Med 2008; 8: 768-73.
63. Neau DB, Gilbert NC, Bartlett SG, Boeglin W, Brash AR, Newcomer ME. The 1.85 A structure of an 8R-lipoxygenasesuggests a general model for lipoxygenase productspecificity. Biochemistry 2009; 48: 7906-15.
64. Wecksler AT, Jacquot C, van der Donk WA, Holman TR. Mechanistic investigations of human reticulocyte 15- andplatelet 12-lipoxygenases with arachidonic acid. Biochemistry 2009; 48: 6259-67.
65. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure ofhuman cyclooxygenase-2. Nat Struct Biol 1996; 3: 927-33.
66. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-42.
67. Tresaugues L, Moche M, Arrowsmith CH, et al. Crystalstructure of the lipoxygenase domain of human Arachidonate 12-lipoxygenase, 12S-type. Submitted. PDB entry 3D3L.
68. Deschamps JD, Gautschi JT, Whitman S, et al. Discovery ofplatelet-type 12-human lipoxygenase selective inhibitors byhigh-throughput screening of structurally diverse libraries. Bioorg Med Chem 2007; 15: 6900-8.
69. Vasquez-Martinez Y, Ohri RV, Kenyon V, Holman TR, Sepulveda-Boza S. Structure-activity relationship studies offlavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorg Med Chem 2007; 15: 7408-25.
70. Somvanshi RK, Singh AK, Saxena M, Mishra B, Dey S. Development of novel peptide inhibitor of Lipoxygenasebased on biochemical and BIAcore evidences. Biochim Biophys Acta 2008; 1784: 1812-7.
71. Cassidy CE, Setzer WN. Cancer-relevant biochemicaltargets of cytotoxic Lonchocarpus flavonoids: a moleculardocking analysis. J Mol Model 2010; 16: 311-26.
72. Node K, Huo Y, Ruan X, et al. Anti-inflammatory propertiesof cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-9.
73. Williams PA, Cosme J, Vinkovic DM, et al. Crystal structuresof human cytochrome P450 3A4 bound to metyrapone andprogesterone. Science 2004; 305: 683-6.
74. Niknami M, Dong Q, Witting PK. Pitfalls in the use ofarachidonic acid oxidation products to assign lipoxygenaseactivity in cancer cells. Free Radic Res 2009; 43: 951-6.
75. Jiang WG, Douglas-Jones A, Mansel RE. Levels ofexpression of lipoxygenases and cyclooxygenase-2 inhuman breast cancer. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 275-81.
76. Shappell SB, Manning S, Boeglin WE, et al. Alterations inlipoxygenase and cyclooxygenase-2 catalytic activity andmRNA expression in prostate carcinoma. Neoplasia 2001; 3: 287-303.
77. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expressionof lipoxygenase in human prostate cancer and growthreduction by its inhibitors. Int J Oncol 2004; 24: 821-7.
78. Yang P, Collin P, Madden T, et al. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 2003; 55: 281-91.
79. Krishnamoorthy S, Jin R, Cai Y, et al. 12-Lipoxygenase andthe regulation of hypoxia-inducible factor in prostate cancercells. Exp Cell Res 2010; 316: 1706-15.
80. Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J and Newman RA. Zyflamend-mediated inhibition of humanprostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation. Cancer Biol Ther 2007; 6: 228-36.
81. Cai Y, Lee YF, Li G, et al. A new prostate cancer therapeuticapproach: combination of androgen ablation with COX-2inhibitor. Int J Cancer 2008; 123: 195-201.
82. Jia RP, Xu LW, Su Q, et al. Cyclooxygenase-2 expression isdependent upon epidermal growth factor receptor expressionor activation in androgen independent prostate cancer. Asian J Androl 2008; 10: 758-64.
83. Jenkins CM, Cedars A, Gross RW. Eicosanoid signallingpathways in the heart. Cardiovasc Res 2009; 82: 240-9.
84. Berglund L, Bjorling E, Oksvold P, et al. A genecentricHuman Protein Atlas for expression profiles based onantibodies. Mol Cell Proteomics 2008; 7: 2019-27.
85. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collectionof 18,000 cancer gene expression profiles. Neoplasia 2007; 9: 166-80.
86. Jaśkiewicz K, Iżycka-Świeszewska E, Janiak M, et al. Platelet 12-lipoxygenase and stem cells in Barrett'sesophagus. Oncol Rep 2010; submitted.
87. Aleem AM, Wells L, Jankun J, et al. Human platelet 12-lipoxygenase: naturally occurring Q 261/R 261 variants and N544L mutant show altered activity but unaffected substratebinding and membrane association behavior. Int J Mol Med 2009; 24: 759-64.
88. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematicreviews of the clinical effectiveness and cost-effectiveness ofproton pump inhibitors in acute upper gastrointestinalbleeding. Health Technol Assess 2007; 11: iii-iv, 1-164.
89. Park SH, Cho CS, Lee OY, et al. Comparison of Preventionof NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 2007; 40: 148-55.
90. de Boer MA, van Gemund N, Scherjon SA, Kanhai HH. Lowdose sulprostone for termination of second and thirdtrimester pregnancies. Eur J Obstet Gynecol Reprod Biol 2001; 99: 244-8.
91. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration ofmisoprostol. Hum Reprod 2002; 17: 332-6.
92. Weeks A, Alfirevic Z, Faundes A, Hofmeyr GJ, Safar P, Wing D. Misoprostol for induction of labor with a live fetus. Int J Gynaecol Obstet 2007; 99 Suppl 2: S 194-7.
93. Moraes Filho OB, Albuquerque RM, Cecatti JG. Arandomized controlled trial comparing vaginal misoprostolversus Foley catheter plus oxytocin for labor induction. Acta Obstet Gynecol Scand 2010; 89: 1045-52.
94. Dupont C, Touzet S, Colin C, et al. Incidence andmanagement of postpartum haemorrhage following thedissemination of guidelines in a network of 16 maternity unitsin France. Int J Obstet Anesth 2009; 18: 320-27.
95. Hagenaars M, Knape JT, Backus EM. Pulmonary oedemaafter high infusion rate of sulprostone. Br J Anaesth 2009; 102: 281-2.
96. Ikushima I, Hirai T, Ishii A, Yamashita Y. Combined stentplacement and high dose PGE1 drip infusion for chronicocclusion of the superficial femoral artery as a modality tosalvage chronic critical limb ischemia. Eur J Radiol 2008; 66: 95-9.
97. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for criticallimb ischaemia. Cochrane Database Syst Rev 2010:CD006544.
98. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy forerectile dysfunction. J Sex Med 2010; 7: 524-40.
99. Benedict N, Seybert A, Mathier MA. Evidence-basedpharmacologic management of pulmonary arterialhypertension. Clin Ther 2007; 29: 2134-53.
100. Skoro-Sajer N, Lang I. The role of treprostinil in themanagement of pulmonary hypertension. Am J Cardiovasc Drugs 2008; 8: 213-7.
101. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprostinfusion in patients with Raynaud phenomenon secondary tosystemic sclerosis. A multicenter, placebo-controlled, doubleblindstudy. Ann Intern Med 1994; 120: 199-206.
102. Sutton A, Gouws P, Ropo A. Tafluprost, a new potentprostanoid receptor agonist: a dose-response study onpharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther 2008; 46: 400-6.
103. Curran MP. Bimatoprost: a review of its use in open-angleglaucoma and ocular hypertension. Drugs Aging 2009; 26: 1049-71.
104. Jeng KCG, Hou RCW. Sesamin and sesamolin: nature'stherapeutic lignans. Curr Enzyme Inhib 2005; 1: 11-20.
105. Serhan CN, Chiang N, Van Dyke TE. Resolvinginflammation: dual anti-inflammatory and pro-resolution lipidmediators. Nat Rev Immunol 2008; 8: 349-61.
106. Oates JA. The 1982 Nobel Prize in Physiology or Medicine. Science 1982; 218: 765-8.